 "GlaxoSmithKline sees hit from China corruption scandal")
GlaxoSmithKline , rocked by charges of corruption in China, reported a modest two per cent rise in second-quarter group sales on Wednesday but said the bribery scandal would inevitably have an impact. "Clearly, we are likely to see some impact to our performance in China as a result of the current investigation, but it is too early to quantify the extent of this," Chief Executive Andrew Witty said.
GSK's worldwide sales in the quarter were £6.62 billion ($10.17 billion), generating core earnings per share (EPS) up one per cent at 26.3 pence. Analysts, on average, had forecast sales of £6.60 billion and core EPS, which excludes certain items, of 26.2p, according to Thomson Reuters.
The company reiterated that it expected sales growth for the year to be around 1 per cent in local currency terms, with EPS rising by between three and four per cent.
GSK's worldwide sales in the quarter were £6.62 billion ($10.17 billion), generating core earnings per share (EPS) up one per cent at 26.3 pence. Analysts, on average, had forecast sales of £6.60 billion and core EPS, which excludes certain items, of 26.2p, according to Thomson Reuters.
The company reiterated that it expected sales growth for the year to be around 1 per cent in local currency terms, with EPS rising by between three and four per cent.
You’ve reached your limit of {{free_limit}} free articles this month.
Subscribe now for unlimited access.
Already subscribed? Log in
Subscribe to read the full story →*Subscribe to Business Standard digital and get complimentary access to The New York Times
Smart Quarterly
₹900
3 Months
₹300/Month
SAVE 25%
Smart Essential
₹2,700
1 Year
₹225/Month
SAVE 46%
*Complimentary New York Times access for the 2nd year will be given after 12 months
Super Saver
₹3,900
2 Years
₹162/Month
Subscribe
Renews automatically, cancel anytime
Here’s what’s included in our digital subscription plans
Exclusive premium stories online
Over 30 premium stories daily, handpicked by our editors
Complimentary Access to The New York Times
News, Games, Cooking, Audio, Wirecutter & The Athletic
Business Standard Epaper
Digital replica of our daily newspaper — with options to read, save, and share
Curated Newsletters
Insights on markets, finance, politics, tech, and more delivered to your inbox
Market Analysis & Investment Insights
In-depth market analysis & insights with access to The Smart Investor
Archives
Repository of articles and publications dating back to 1997
Ad-free Reading
Uninterrupted reading experience with no advertisements
Seamless Access Across All Devices
Access Business Standard across devices — mobile, tablet, or PC, via web or app
SAVE 25%